LAUSR

Mixed suspension, mixed product removal (MSMPR) crystallizers are widely implemented for the continuous crystallization of active pharmaceutical ingredients (APIs), allowing enhanced efficiency, flexibility, and product quality compared to currently dominant batch crystallizer designs. Establishing cost-effective continuous crystallization process configurations for societally and economically important APIs is essential to ensure the successful implementation of end-to-end continuous pharmaceutical manufacturing (CPM) campaigns. Process modeling and optimization allow rapid, systematic comparative technoeconomic evaluations. This paper pursues total cost minimization of different crystallizer configurations of three APIs—cyclosporine, paracetamol, and aliskiren hemifumarate—whose continuous MSMPR crystallization has been experimentally demonstrated. Nonlinear optimization for total cost minimization is implemented for one to three crystallizers for different plant API capacities with crystallizer tempera...